Skip to main content
Article thumbnail
Location of Repository

Risk of suicide during treatment with venlafaxine, italopram, fluoxetine, and dothiepin : retrospective cohort study

By Annalisa Rubino, Neil Roskell, Pat Tennis, Daniel Mines, Scott Weich and Elizabeth Andrews


Objective To compare the risk of suicide in adults usingthe\ud antidepressant venlafaxine compared with citalopram,\ud fluoxetine, and dothiepin.\ud Design Retrospective cohort study. Setting UK General Practice Research Database. Participants 219 088 patients, aged 18-89 years, who were prescribed venlafaxine, citalopram, fluoxetine, or dothiepin from 1995 to 2005.\ud Main outcome measures Completed suicide and attempted\ud suicide.\ud Results Venlafaxine users had a higher burden of risk factors for suicide, includingprevious suicide attempts and proxies for severe depression or depression that was difficult to treat. In the analysis for completed suicides, unadjusted and adjusted hazard ratios for venlafaxine compared with citalopram were 2.44 (95% confidence interval 1.12 to 5.31) and 1.70 (0.76 to 3.80), for venlafaxine compared with fluoxetine were 2.85 (1.37 to 5.94) and 1.63 (0.74 to 3.59), and for venlafaxine compared with dothiepin were 2.54 (1.07 to 6.02) and 1.31 (0.53 to 3.25).\ud Compared with other study drugs, venlafaxine was also\ud associated with an increased risk of attempted suicide, but\ud adjustment for measured confounders substantially reduced the hazard ratios.\ud Conclusions Venlafaxine use was consistently associated with\ud higher risk of suicide compared with citalopram, fluoxetine, and dothiepin. Venlafaxine users had a higher burden of suicide risk factors, however, and adjustment for measured confounders substantially reduced the excess risks. Since the secondary data used in this analysis allowed only indirect and partial measurements of potential confounders, it is possible that residual confounding explains much, if not all, of the observed\ud excess risk

Topics: RM, RS
Publisher: BMJ Group
Year: 2006
OAI identifier:

Suggested articles


  1. (2005). 2 FDA reviews data for antidepressant use in adults. doi
  2. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. doi
  3. Antidepressants and suicide. doi
  4. Antidepressants and the risk of suicidal behaviors. doi
  5. Assault victimization and suicidal ideation or behavior within a national sample of US adults. doi
  6. (1992). Comparison of frequencies of suicidal tendencies among patients receivingfluoxetine, lofepramine, miansetin, or trazodone.
  7. Estimatingand correctingfor confoundingmisclassification.
  8. (1997). Leufkens HG. Channelingof three newly introduced antidepressants to patients not respondingsatisfactorily to previous treatment.
  9. Mortality of cystic fibrosis patients treated with tobramycin for inhalation. doi
  10. or venlafaxine-XR after failure of SSRIs for depression. doi
  11. Parkinson’s disease, multiple sclerosis, diabetes, cirrhosis, myocardial infarction, stroke, renal failure, respiratory diseases, and arthritis.
  12. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. doi
  13. Risk factors for suicide in youngpeople suffering from schizophrenia: a long-term follow-up study. doi
  14. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drugcompany data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. doi
  15. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data [see comment]. doi
  16. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
  17. Suicidality in pediatric patients treated with antidepressant drugs. doi
  18. Suicide and self-harm followingprescription of SSRIs and other antidepressants: confoundingby indication.
  19. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. doi
  20. Suicide risk followingchild sexual abuse. doi
  21. Suicide risk in placebo-controlled studies of major depression. doi
  22. (1205). Table 1 Frequency distribution of population characteristics by antidepressant use in completed suicide analysis. Values are percentages (numbers) unless stated otherwise Characteristic Venlafaxine Citalopram Fluoxetine Dothiepin No of participants
  23. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. doi
  24. (1997). The UK general practice research database. doi
  25. (1995). Time zero was set at 1 doi
  26. (1998). Use of the UK general practice research database for pharmacoepidemiology. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.